Parkside Financial Bank & Trust Acquires 871 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Parkside Financial Bank & Trust raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 806.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 979 shares of the company’s stock after buying an additional 871 shares during the period. Parkside Financial Bank & Trust’s holdings in Amphastar Pharmaceuticals were worth $36,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. D.A. Davidson & CO. purchased a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at $417,000. Principal Financial Group Inc. lifted its holdings in Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Principal Financial Group Inc. now owns 207,978 shares of the company’s stock valued at $7,722,000 after buying an additional 5,961 shares in the last quarter. Rhumbline Advisers boosted its position in Amphastar Pharmaceuticals by 1.4% in the 4th quarter. Rhumbline Advisers now owns 87,327 shares of the company’s stock valued at $3,242,000 after buying an additional 1,213 shares during the period. Polaris Capital Management LLC bought a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $910,000. Finally, Yorktown Management & Research Co Inc purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth approximately $245,000. Institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Piper Sandler lowered Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus price target of $50.33.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the transaction, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Trading Down 3.2 %

NASDAQ:AMPH opened at $27.52 on Tuesday. The firm has a 50-day simple moving average of $34.74 and a 200-day simple moving average of $42.57. Amphastar Pharmaceuticals, Inc. has a one year low of $26.98 and a one year high of $53.96. The firm has a market cap of $1.32 billion, a P/E ratio of 9.17, a P/E/G ratio of 2.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.